Kinfo
Compass Therapeutics Inc. logo

Compass Therapeutics Inc.

CMPXNASDAQHealthcare·US · USD
$2.26
-0.11 (-4.64%)
Prices as of August 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap407.00M USD
Enterprise value225.95M USD
Trailing P/E-5.39
Forward P/E-4.21
PEG ratio0.76
Price / sales0.00
Price / book2.39
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-33.03%
Return on equity-56.66%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-81.01M USD
Net income-73.45M USD
Diluted EPS-$0.39
Rev. growth (YoY)0.00%
Balance sheet
Total cash179.88M USD
Total debt9.63M USD
Debt / equity5.80
Current ratio11.22
Book value / share$0.92
Cash flow (TTM)
Operating cash flow-56.11M USD
Levered free cash flow-31.36M USD
Shares & price
Shares outstanding180.09M
Float118.04M
Held by institutions96.55%
Beta0.82
50-day MA$2.09
200-day MA$4.14
52-week high$6.88
52-week low$1.61
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.11-0.13−18.18%2026-07-200.340.36+5.88%2026-06-041.451.64+13.10%2026-05-05-0.10-0.10+0.00%2026-04-130.300.30+0.00%
About Compass Therapeutics Inc.

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody therapeutics, primarily in oncology. The company engages the immune system to treat multiple human diseases, with its scientific orientation centered on the relationship between angiogenesis, the immune system, and tumor growth. Its innovative platform features common light chain-focused antibody discovery, human display technology for antibody tuning, Stitchmabs, and highly modular, manufacturable bispecific antibody candidates. Key product candidates include CTX-009, CTX-471, CTX-10726, VEGF-A bispecifics, and CTX-8371, targeting various aspects of cancer immunotherapy. Compass Therapeutics Inc. operates within the health technology sector, specifically pharmaceuticals, advancing therapies that modulate immune responses against tumors. Founded in 2014 and headquartered in Boston, Massachusetts, the company plays a role in the competitive biopharmaceutical market by pioneering next-generation antibody-based treatments for unmet medical needs in oncology.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Employees
39
Headquarters
Boston, MA, United States

Frequently asked questions about Compass Therapeutics Inc.